Perrigo Company plc Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Perrigo Company plc (PRGO) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2025-02-28
- Perrigo Company plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Perrigo Company plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $4.90M.
- Perrigo Company plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Perrigo Company plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2021 was $11.90M, a 440.91% increase from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 |
| 2023-12-31 | $4.90M 10-K · filed 2025-02-28 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-27 |
| 2021-12-31 | $11.90M 10-K · filed 2023-02-28 |
| 2020-12-31 | $2.20M 10-K · filed 2022-03-01 |
| 2019-12-31 | $23.50M 10-K · filed 2021-03-01 |
| 2018-12-31 | $1.10M 10-K · filed 2020-02-27 |
| 2017-12-31 | $100.00K 10-K · filed 2019-02-27 |
| 2016-12-31 | $5.30M 10-K · filed 2018-03-01 |
| 2015-06-27 | $1.70M 10-K · filed 2017-05-22 |
| 2014-06-28 | $1.50M 10-KT · filed 2016-02-25 |
| 2013-06-29 | $1.60M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |